Singapore and 10 other countries approve dengue vaccine after 20-year wait

PARIS - Sanofi Pasteur, Sanofi's vaccines unit, said on Tuesday that its dengue vaccine, Dengvaxia, had received market approval in eleven countries.

To date the vaccine has been approved in Mexico, the Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore, the statement said.

Dengue fever is a mosquito-borne disease caused by four virus serotypes (1 to 4) as categorised by the World Health Organisation. Overall, the disease is seen as a threat to about half of the world's population. Some 400 million people are believed to be infected annually.

The dengue vaccine is the culmination of 20 years of Sanofi Pasteur's commitment to discover and develop a vaccine against dengue for priority launch in Latin American and Asian countries where dengue is a major public health priority.